This inventor holds 1 USPTO granted patent. Top assignees: Imperial Cancer Research Technology. Ldt., Transgene S.a.. Active years: 2011.
Company Filing History:
1 out of 1 
1 out of 159 
Years Active: 2011
Title: The Innovative Contributions of Rienk Offringa
Introduction
Rienk Offringa is a notable inventor based in Leiden, Netherlands. He has made significant contributions to the field of immunology, particularly in the development of methods for identifying T cell responses. His work has implications for therapeutic applications in cancer treatment.
Latest Patents
Rienk Offringa holds a patent titled "Method of identifying a MHC class I restricted T cell response." This patent describes peptides and polypeptides derived from the MUC-1 polypeptide that can activate Cytotoxic T Lymphocyte (CTL) responses. It also includes analogues of these peptides and polypeptides, as well as nucleotide sequences encoding them. The patent outlines therapeutic uses and provides indications for selecting appropriate minimal antigenic MUC-1 polypeptides based on the HLA-type of the patient being treated or tested.
Career Highlights
Throughout his career, Rienk Offringa has worked with various organizations, including Transgene S.A. and Imperial Cancer Research Technology Ltd. His expertise in immunology and T cell responses has positioned him as a valuable contributor to advancements in cancer therapies.
Collaborations
Rienk Offringa has collaborated with notable colleagues such as Lukas Carl Heukamp and Cornelis Johanna Maria Melief. These partnerships have furthered research and development in the field of immunology.
Conclusion
Rienk Offringa's innovative work and patent contributions have made a significant impact in the field of immunology. His research continues to influence therapeutic strategies for cancer treatment.